Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117	BIOHAVEN IRELAND	CGRP receptor antagonists	Feb, 2031 (8 years from now)
US8759372	BIOHAVEN IRELAND	N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt	Feb, 2033 (10 years from now)
CN102656159A	BIOHAVEN IRELAND	Cgrp Receptor Antagonists	Oct, 2030 (8 years from now)
CN102656159B	BIOHAVEN IRELAND	Cgrp Receptor Antagonists	Oct, 2030 (8 years from now)
CN104136437A	BIOHAVEN IRELAND	N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate	Feb, 2033 (10 years from now)
CN104136437B	BIOHAVEN IRELAND	N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate	Feb, 2033 (10 years from now)
IN308116B	BIOHAVEN IRELAND	Cgrp Receptor Antagonists	Oct, 2030 (8 years from now)
IN201203373P4	BIOHAVEN IRELAND	Cgrp Receptor Antagonists	Oct, 2030 (8 years from now)
EP2488512A1	BIOHAVEN IRELAND	Cgrp Receptor Antagonists	Oct, 2030 (8 years from now)
EP2488512B1	BIOHAVEN IRELAND	Cgrp Receptor Antagonists	Oct, 2030 (8 years from now)
EP2820016A1	BIOHAVEN IRELAND	N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt	Feb, 2033 (10 years from now)
EP3254681A1	BIOHAVEN IRELAND	N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt	Feb, 2033 (10 years from now)
EP3254681B1	BIOHAVEN IRELAND	N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt	Feb, 2033 (10 years from now)
EP2820016B1	BIOHAVEN IRELAND	N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt	Feb, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724	BIOHAVEN IRELAND	Rimegepant for CGRP related disorders	Mar, 2039 (16 years from now)

Drugs and Companies using RIMEGEPANT SULFATE ingredient

Treatment: Acute treatment of migraine with or without aura in adults; preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
EQ 75MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.